In vitro activity of new quinolones against Clostridium difficile
- PMID: 11157906
- DOI: 10.1093/jac/47.2.195
In vitro activity of new quinolones against Clostridium difficile
Abstract
We evaluated the in vitro activities of ofloxacin, levofloxacin, grepafloxacin, trovafloxacin and ciprofloxacin against Clostridium difficile. The MIC(90) was 128 mg/L for ofloxacin and levofloxacin, 64 mg/L for ciprofloxacin, 16 mg/L for grepafloxacin and 8 mg/L for trovafloxacin. Thirty per cent of isolates were resistant to trovafloxacin, and rates of resistance to ofloxacin, levofloxacin, grepafloxacin and ciprofloxacin were considerably higher. None of the antimicrobials studied would be a reliable therapeutic option against C. difficile. Whether some of the new fluoroquinolones can induce C. difficile-associated diarrhoea remains to be answered.
Similar articles
-
In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.J Antimicrob Chemother. 2000 Oct;46(4):551-6. doi: 10.1093/jac/46.4.551. J Antimicrob Chemother. 2000. PMID: 11020251
-
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.Antimicrob Agents Chemother. 2001 Mar;45(3):673-8. doi: 10.1128/AAC.45.3.673-678.2001. Antimicrob Agents Chemother. 2001. PMID: 11181341 Free PMC article.
-
Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.J Antimicrob Chemother. 2000 Apr;45 Suppl 1:41-6. doi: 10.1093/jac/45.suppl_3.41. J Antimicrob Chemother. 2000. PMID: 10824031
-
Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.J Appl Microbiol. 2018 Nov;125(5):1518-1525. doi: 10.1111/jam.14035. Epub 2018 Aug 20. J Appl Microbiol. 2018. PMID: 29957893
-
Quinolone activity against anaerobes.Drugs. 1999;58 Suppl 2:60-4. doi: 10.2165/00003495-199958002-00012. Drugs. 1999. PMID: 10553708 Review.
Cited by
-
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02100-16. doi: 10.1128/AAC.02100-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28223393 Free PMC article.
-
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. doi: 10.1128/AAC.49.2.488-492.2005. Antimicrob Agents Chemother. 2005. PMID: 15673722 Free PMC article.
-
Fluoroquinolone use and Clostridium difficile-associated diarrhea.Emerg Infect Dis. 2003 Jun;9(6):730-3. doi: 10.3201/eid0906.020385. Emerg Infect Dis. 2003. PMID: 12781017 Free PMC article.
-
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. doi: 10.1128/AAC.46.11.3418-3421.2002. Antimicrob Agents Chemother. 2002. PMID: 12384345 Free PMC article.
-
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.Antimicrob Agents Chemother. 2009 Jun;53(6):2463-8. doi: 10.1128/AAC.01252-08. Epub 2009 Apr 13. Antimicrob Agents Chemother. 2009. PMID: 19364867 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources